Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.03% $0.350
America/New_York / 24 apr 2024 @ 10:19
FUNDAMENTALS | |
---|---|
MarketCap: | 1.496 mill |
EPS: | -2.81 |
P/E: | -0.120 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 4.27 mill |
Avg Daily Volume: | 0.0192 mill |
RATING 2024-04-24 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.120 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.120 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.309 - 0.391 ( +/- 11.71%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-20 | Windham-bannister Susan Richards | Buy | 6 835 | Stock Option (right to buy) |
2023-06-20 | Satz Brian | Buy | 6 835 | Stock Option (right to buy) |
2023-06-20 | Kisner Daniel L | Buy | 6 835 | Stock Option (right to buy) |
2023-06-20 | Jackson Jonathan | Buy | 6 835 | Stock Option (right to buy) |
2023-06-20 | Fuhrmann Rochelle | Buy | 6 835 | Stock Option (right to buy) |
INSIDER POWER |
---|
76.59 |
Last 87 transactions |
Buy: 7 685 070 | Sell: 109 431 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.350 (0.03% ) |
Volume | 0.0070 mill |
Avg. Vol. | 0.0192 mill |
% of Avg. Vol | 36.24 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.